Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Yuyu Pharma, Inc..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Yuyu Pharma, Inc.
ClinicalTrials.gov Identifier:
NCT01536210
First received: January 9, 2012
Last updated: February 15, 2012
Last verified: October 2011
  Purpose

This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD.


Condition Intervention Phase
Mental Disorders
Drug: YY-162
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks

Resource links provided by NLM:


Further study details as provided by Yuyu Pharma, Inc.:

Primary Outcome Measures:
  • Korea-ADHD Rating scale [ Time Frame: within the first 8 weeks (plus or minus 5 days) after adminitration ] [ Designated as safety issue: No ]
    Validated questionnaire about core ADHD symptoms(Korea-ADHD Rating scale) filled out by patents at baseline, after 8 weeks.


Secondary Outcome Measures:
  • IOWA conner's rating scale [ Time Frame: baseline, after 2, 4, and 8 weeks ] [ Designated as safety issue: No ]
    Validated questionnaire about core ADHD symptoms(IOWA Conner's rating scale) filled out by parents at baseline, after 2,4 weeks and closeout

  • Clinical Global Impression(Severity and Improvement) [ Time Frame: baseline, after 2, 4, and 8 weeks ] [ Designated as safety issue: No ]
    Clinical Global Impression(Severity and Improvement)rated by treating physician at baseline, after2,4 weeks and closeout

  • Advanced Test of Attention [ Time Frame: baseline and 8 weeks ] [ Designated as safety issue: No ]
    Advanced Test of Attention and baseline and closeout Attention Diagnostic system(visual and auditory) at baseline and closeout

  • children's color trails test and stroop test [ Time Frame: baseline and 8 weeks ] [ Designated as safety issue: No ]
    Children's color trails test and stroop test at baseline and closeout

  • Intelligence test(from KEDI-WISC) [ Time Frame: screening and 8 weeks ] [ Designated as safety issue: No ]
    Intelligence test(from KEDI-WISC)at screening and closeout


Estimated Enrollment: 144
Study Start Date: December 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: YY-162

YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)

1T/Three times a day(Tid) for 8 weeks, PO medication

Drug: YY-162
YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
Other Name: combination of Ginkgo extract and Ginseng extract
Placebo Comparator: Placebo
Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
Drug: Placebo
Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
Other Name: Placebo

Detailed Description:

This is Double-Blind, two arms, multi-center, Interventional, 8 weeks study starting with YY-162(Combination of Ginkgo extract and Ginseng extract)in children with ADHD. Assessment of efficacy and safety will be performed at the baseline, weeks 2, 4 and 8. At the first visit, a full psychiatric history, demographic date and physical examination will be undertaken. Throughout the study, the following procedures, documentations and evaluations will performed; K-ARS, IOWA conner's rating scale, CGI-S/I, ATA, Children's color trails test and stroop test, intelligence test(from KEDI-WISC)and adverse event reporting.

  Eligibility

Ages Eligible for Study:   6 Years to 15 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Mele and female subjects aged from 6 to 15
  • Subjects must meet DSM-IV criteria for ADHD based-on the K-Schedule for affective disorder and schizophrenia(K-SADS-PL-K)interview
  • Subjects signed a written consent form voluntarily
  • Patient's assent to participate in the study and written informed consent form signed by one of the parents, parent surrogates or legal guardian.
  • Subjects who can keep visit schedule and whose parent/parent surrogates or legal guardian can willingly complete assessments defined in the study protocol.
  • Subjects/parents, parent surrogates or legal guardian who can understand the participation of the study and voluntarily withdraw from the study at any time.

Exclusion Criteria:

  • Subjects who have difficulty swallowing tablet.
  • Subjects who have known allergy to plant extracts.
  • Subjects who meet DSM-IV diagnostic criteria for current major depressive disorder or anxiety disorder requiring drug therapy.
  • Subjects who have any history of bipolar disorder, psychotic disorder, and substance use disorder, have been diagnosed with a pervasive developmental disorder, organic brain disease and seizure disorder.
  • Subjects who have significant suicidal ideation.
  • Subjects with mental retardation.
  • Subjects with Tourette's syndrome requiring drug therapy.
  • Subjects who have been administrated Methylphenidate or Atomoxetine within recent 3 months and Ginkgo extract or Ginseng extract within recent 1 month.
  • Subjects who currently have a significant medical conditions(e.g. diseases of cardiovascular, hepatic, renal, respiratory, glaucoma)
  • Subjects who have abnormalities in the ECG or show clinically significant abnormalities of laboratory results including serum chemistries and hematology.
  • subjects who are currently taking alpha-2 adrenergic receptor agonist, antidepressant, antipsychotic, benzodiazepines, modafinil, anticonvulsant.
  • subjects who receive psychosocial treatment during the drug trial.
  • Subjects who are not able to swallow the study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01536210

Contacts
Contact: Soochurl Cho, MD,PhD 82-2-2072-3648 soochurl@snu.ac.kr
Contact: Kyeongsuk Seo, BS 82-2-2253-6600 ext 269 ksseo@yuyu.co.kr

Locations
Korea, Republic of
Hallym University Hospital Recruiting
Anyang-si, Korea, Republic of, 431-070
Contact: Hyun Ju Hong, MD,PhD    82-31-380-3750    honghj88@gmail.com   
Contact: Kyeongsuk Seo, BS    82-2-2253-6600    ksseog@yuyu.co.kr   
Principal Investigator: Hyun Ju Hong, MD, PhD         
Inje University Ilsan Paik Hospital Recruiting
Goyang-Si, Korea, Republic of, 411-706
Contact: EunJin Park, MD    82-31-910-7544    uma99@hanmail.net   
Contact: Kyeongsuk Seo, BS    82-2-2253-6600    ksseo@yuyu.co.kr   
Principal Investigator: EunJin Park, MD         
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 110-744
Contact: Soo-Churl Cho, MD, PhD    83-2-2072-3648    soochurl@snu.ac.kr   
Contact: Kyeongsuk Seo, BS    82-2-2253-6600    ksseo@yuyu.co.kr   
Principal Investigator: Soo-Churl Cho, MD, PhD         
Sponsors and Collaborators
Yuyu Pharma, Inc.
Investigators
Principal Investigator: SooChurl Cho, MD, PhD Seoul National University Hospital
Principal Investigator: HyunJu Hong, MD, PhD Hallym University Hospital
Principal Investigator: EunJin Park, MD Inje University
  More Information

Additional Information:
Publications:
Responsible Party: Yuyu Pharma, Inc.
ClinicalTrials.gov Identifier: NCT01536210     History of Changes
Other Study ID Numbers: YY-162 (b)
Study First Received: January 9, 2012
Last Updated: February 15, 2012
Health Authority: Korea: Food and Drug Administration

Keywords provided by Yuyu Pharma, Inc.:
ADHD(attention Deficit Hyperactivity Disorder)

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Schizophrenia and Disorders with Psychotic Features
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on July 29, 2014